These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19472103)

  • 1. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate.
    Haider A; Gooren LJ; Padungtod P; Saad F
    Exp Clin Endocrinol Diabetes; 2010 Mar; 118(3):167-71. PubMed ID: 19472103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men.
    Haider A; Gooren LJ; Padungtod P; Saad F
    Andrologia; 2009 Feb; 41(1):7-13. PubMed ID: 19143723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome.
    Saad F; Gooren L; Haider A; Yassin A
    Andrologia; 2008 Feb; 40(1):44-8. PubMed ID: 18211301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation.
    Giltay EJ; Haider A; Saad F; Gooren LJ
    Andrologia; 2008 Dec; 40(6):398-400. PubMed ID: 19032692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study.
    Kalinchenko SY; Tishova YA; Mskhalaya GJ; Gooren LJ; Giltay EJ; Saad F
    Clin Endocrinol (Oxf); 2010 Nov; 73(5):602-12. PubMed ID: 20718771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.
    Saad F; Gooren LJ; Haider A; Yassin A
    J Androl; 2008; 29(1):102-5. PubMed ID: 17916569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
    Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
    J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
    Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
    BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.
    Giltay EJ; Tishova YA; Mskhalaya GJ; Gooren LJ; Saad F; Kalinchenko SY
    J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome.
    Kerner A; Avizohar O; Sella R; Bartha P; Zinder O; Markiewicz W; Levy Y; Brook GJ; Aronson D
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):193-7. PubMed ID: 15499043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypogonadism and metabolic syndrome: implications for testosterone therapy.
    Makhsida N; Shah J; Yan G; Fisch H; Shabsigh R
    J Urol; 2005 Sep; 174(3):827-34. PubMed ID: 16093964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral testosterone supplementation and chronic low-grade inflammation in elderly men: a 26-week randomized, placebo-controlled trial.
    Nakhai-Pour HR; Grobbee DE; Emmelot-Vonk MH; Bots ML; Verhaar HJ; van der Schouw YT
    Am Heart J; 2007 Dec; 154(6):1228.e1-7. PubMed ID: 18035098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative androgen deficiency in relation to obesity and metabolic status in older men.
    Chen RY; Wittert GA; Andrews GR
    Diabetes Obes Metab; 2006 Jul; 8(4):429-35. PubMed ID: 16776750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM; Heinemann L; Morales A; Pexman-Fieth C
    Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate.
    Minnemann T; Schubert M; Hübler D; Gouni-Berthold I; Freude S; Schumann C; Oettel M; Ernst M; Mellinger U; Sommer F; Krone W; Jockenhövel F
    Aging Male; 2007 Sep; 10(3):155-8. PubMed ID: 17701659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?
    Kaplan SA; Meehan AG; Shah A
    J Urol; 2006 Oct; 176(4 Pt 1):1524-7; discussion 1527-8. PubMed ID: 16952672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of 2 years of administration of parenteral testosterone undecanoate on the metabolic syndrome and on non-alcoholic liver steatosis and C-reactive protein.
    Haider A; Gooren LJ; Padungtod P; Saad F
    Horm Mol Biol Clin Investig; 2010 Jan; 1(1):27-33. PubMed ID: 25961969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months.
    Haider A; Gooren LJ; Padungtod P; Saad F
    Andrologia; 2010 Dec; 42(6):349-55. PubMed ID: 21105885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.